[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month (past submissions can be found on his author page here). Like all of our authors, he chooses his own topics and […]
Articles
[ed note: Michael Jorrin is longtime medical writer who has been sharing his thoughts with our readers as “Doc Gumshoe” for several years (he’s not a doctor, I gave him the name). He generally covers medical and health news and sometimes health promotions and hype, but he rarely opines about investments or specific stocks. All […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, writes for us a couple times a month on medicine and health issues. He is not a physician, but explains the science and the data well, and helps provide some background understanding and perspective that often benefits both investors and folks who are attentive […]
[ed note: Michael Jorrin, who I dubbed “Doc Gumshoe,” is a longtime medical writer (not a doctor) who shares his thoughts with Gumshoe readers a couple times a month. He usually does not specifically cover investment ideas, and his words and opinions are his own — his past columns can be found here] Lots of […]
[ed. note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes about non-financial health and medical issues for us a couple times a month. Like all of our authors, he chooses his own topics and his words and opinions are his alone. Enjoy!] While working […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]
[ed note: Michael Jorrin, who I like to call Doc Gumshoe, is a longtime medical writer (not a doctor) who shares his non-investment thoughts with us a couple times a month. I suppose it’s a coincidence that he’s looking at depression at a time when we’re all a bit depressed about the market, but maybe […]
[Michael Jorrin, who I call “Doc Gumshoe,” is a longtime medical writer who writes on health and medicine topics for us from time to time. He is not a doctor, and his commentary is not investment-focused. He chooses his own topics, and, as with all our guest columnists, the words and opinions are his alone […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe,” is a longtime medical writer (not a doctor) who shares his non-investing thoughts with us once or twice a month. His words and thoughts are his own. My eyes are red this time of year, so I read this one with interest.] Just about […]
Your Waistline and Your Lifeline: How Strong is that Link, Really?[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] Let me begin with a disclaimer: I am not skinny, but neither am I fat. This chapter […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] The word “placebo” is the first person singular, future tense, of the Latin verb “placere,” to please […]
[Ed note: Here is our latest piece from “Doc Gumshoe”, who is a medical writer (not a doctor) who shares his wisdom with us at Stock Gumshoe a couple times a month. As always, Michael’s words and opinions are his own.] Lots of analysts and prognosticators give these cholesterol-lowering agents a big thumbs up. The […]
[ed note: today we’re happy to publish the latest thoughts from “Doc Gumshoe”, who is a medical writer (not a doctor) whose work we often feature here at Stock Gumshoe. As always, Michael’s words and opinions are his own … enjoy!] From a purely rational standpoint, hormone replacement therapy for some women who are experiencing […]
[Ed note: Following is another installment from our favorite medical scribe, “Doc Gumshoe” (no, he’s not a doctor). We feature Michael’s commentary every couple weeks or so, and his thoughts and words are his own. “Doc” doesn’t pick stocks, but FDA decisions are a huge driver of investment success for pharmaceutical and biotech companies and […]
[Ed note: Following is another installment from our favorite medical scribe, “Doc Gumshoe” (no, he’s not a doctor). We feature Michael’s commentary every couple weeks or so, and his thoughts and words are his own. “Doc” doesn’t pick stocks, but who knows … maybe you’ll find yourself wanting to understand a biotech company’s migraine drug […]
Robert Morris is helming a biotech-focused stock newsletter that’s called Biotech Supertrader (modesty has no place in the world of newsletter promotions, of course), and I’ve never covered this letter before so I thought I ought to have a look at the latest teaser we’ve been asked about. Morris, incidentally, has been featured in our […]
“Odds are you never heard of this murderous disease that quickly kills more than 250,000 Americans every year. “If your doctor correctly diagnoses it within 24-36 hours of its onset you could live. “If he can’t… and most doctors can’t… your life is a coin toss. “HEADS YOU LIVE TAILS YOU DIE “But this company’s […]
[ed note: We feature the musings of our favorite health and medicine writer, Michael Jorrin, a couple times a month, and we’ve taken the liberty of calling him “Doc Gumshoe” (he’s not a doctor). You’ll find no stock picks in his pieces, but hopefully will get plenty of insight into the medical matters he explains […]
[ed. note: We feature the writings of Doc Gumshoe, our favorite medical scribe, every few weeks here at Stock Gumshoe. He is not a doctor, but we value his insight, research, contrariness and skepticism … and, most importantly, his ability to explain complex health issues for our readers. You can see all of Michael’s previous […]
[ed. note: We feature the writings of Doc Gumshoe, our favorite medical scribe, every few weeks here at Stock Gumshoe. He is not a doctor, but we value his insight, research, contrariness and skepticism … and, most importantly, his ability to explain complex health issues for our readers. He generates a lot of discussion with […]
[ed note: Another piece from “Doc Gumshoe” today — Michael Jorrin is not a doctor, he’s a longtime medical writer who we love because he explains diseases, treatments, and health controversies in a way that makes sense. The words and opinions shared below are his alone. If you’re curious about whether rheumatoid arthritis matters to […]
[ed note: This is the latest in a series of articles from medical writer “Doc Gumshoe” (who, yes, is not actually a doctor) — it’s on the hot topic if antibiotic resistance, and we’ll likely continue to see companies touted and teased that aim to either fight resistant bacteria or clean up hospitals to slow […]
[ed note: Doc Gumshoe is our favorite medical writer, and he usually pops in to explore a topic or answer questions readers have posed a couple times a month — he’s not a medical doctor and, as always, his opinions are his own.] Let’s start this off with a hypothetical case, or rather, three hypothetical […]
[ed note: This is another installment from our favorite medical writer, Doc Gumshoe (no, he’s not a doctor, but we like the way he analyzes and explains medical issues for our readers). Since he’s talking about specific companies this time, we’ve restricted the piece to the Irregulars and have inserted some comments about the stocks […]
[ed. note: We feature the writings of Doc Gumshoe, our favorite medical writer, every few weeks here at Stock Gumshoe. He is not a doctor, but we value his insight, research, contrariness and skepticism … and, most importantly, his ability to explain complex health issues for our readers. He generates a lot of discussion with […]
[Ed. note: Michael Jorrin, who we like to call “Doc Gumshoe,” is not a doctor, he is a longtime medical writer who contributes pieces for us that we hope give a good background or perspective on medical issues (and marketing) for those of us who are as overwhelmed with “live to 150” promises as we […]
The Resveratrol Bust Disappointing, but unsurprising, I say. At this point I’m willing to stake my bet that the wonderful promise of resveratrol isn’t going to pan out. What’s resveratrol? Let’s take a little journey back in our time machine About Resveratrol It goes back at least 70 years, to the discovery by Japanese investigators […]
[ed. note: We’ve been privileged to share with you some “non investment” commentary here from Michael Jorrin, a longtime medical writer who we like to call “Doc Gumshoe” — today he’s got a new piece for us that should help us think skeptically about yet more of the “easy solution” promises people make about health, […]
Does the Supreme Court decision announced June 17th, giving the FDA the right to sue pharmaceutical companies that enter into “pay to delay” agreements with generic drug makers represent a blow to big pharma, a gift to the generic sector, and a boon to consumers? I don’t think so, and here’s why: The situations where […]
[Ed note: if you’re new to Doc Gumshoe, this is our break from investment chatter: He’s our favorite medical writer and he shares his contrarian and thoughtful commentaries with us every now and again. Any opinions and assertions are his own.] It all starts with an unassailable truth: the healthier you are to start with, […]
Today we’re sharing another piece from our medical contributor, “Doc Gumshoe” — we have added the stock tickers to the companies he mentions for your researching convenience, but this survey of the state of cancer research — which will hopefully be good background help to folks trying to understand the basic science behind pitches for […]
The old news, by now a couple of years old, is that the U. S. Preventive Services Task Force (USPSTF) has recommended against routine screening of women aged 40 to 49 years for breast cancer, and also recommended against screening for prostate cancer for men at any age using the prostate-specific antigen (PSA) test. The […]
The one area of the web that has as many “self help” and “miracle solutions” newsletters (and marketing teasers) as personal finance is health — the investing newsletters promise eternal wealth, and the health newsletters promise eternal life (or something dang close). Readers ask us about the crazy marketing for these health newsletters all the […]
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.
More Info
Comments
Will be interesting to see if Travis' recommendation of ATVI changes in light of their dropping a gamer over their banni...
i was wondering the same thing about the shadow training for this? I just purchased his options strategy proceeding the...
Interesting! Memory says that ATVI has been one of David Gardner's reco's & re-reco's over the years and I'm a bit s...
Wasn't Activision Blizzard hit with a class action suit last week for misleading investors about the status of their pa...
jamessko: I so echo your comments on limits and stops. I am truly confounded, especially when facing the horrible & co...
Haven’t looked through the filing yet, but ATVI is on my list to follow up — thanks for the reminder....
Travis, in your last Friday File, you mentioned about Activision Blizzard (ATVI) being tempting. It is down ~13% today....
Every decade gives us our unique capabilities. Activision Blizzard developing particularly dynamically so put a bet on i...
Okay, since the cat's out of the bag, Dis was one of the three companies that had already been recently recommended when...
Improving cash from operations. Activision Blizzard is generally able to produce more consistent profits and cash flow t...
Do you mean Blizzard Entertainment (of World of Warcraft?) Investors have never been able to own them directly (at least...
You're abolutely right about Navellier. I subscribed to his Blue Chip Growth last year and sent them numerous emails ask...
Activision Blizzard may be a great pick. As an old school video game junky let me tell you that in the world of video g...